...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition

 This is great to see and only makes me think that what we have here is the next great step in the evolution of medical treatments. The Zenith employees must be very happy to be on the cusp of something great. They have opened the pathway to the next level of treatments for the human race. It is great to see other Pharmas starting research on the BRD4 domain. Thanks for posting Bear. We are on the right track and just need one of these trials to show results and then things will get interesting.

 

Share
New Message
Please login to post a reply